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Primary hyperoxaluria type I (PH1) is an autosomal-
recessive inborn error of liver metabolism caused
by alanine:glyoxylate aminotransferase (AGT) defi-
ciency. In silico modeling of liver metabolism in
PH1 recapitulated accumulation of known bio-
markers as well as alteration of histidine and hista-
mine levels, which we confirmed in vitro, in vivo,
and in PH1 patients. AGT-deficient mice showed
decreased vascular permeability, a readout of in vivo
histamine activity. Histamine reduction is most likely
caused by increased catabolism of the histamine
precursor histidine, triggered by rerouting of alanine
flux fromAGT to the glutamic-pyruvate transaminase
(GPT, also known as the alanine-transaminase ALT).
Alanine administration reduces histamine levels in
wild-type mice, while overexpression of GPT in PH1
mice increases plasma histidine, normalizes hista-
mine levels, restores vascular permeability, and de-
creases urinary oxalate levels. Our work demon-
strates that genome-scale metabolic models are
clinically relevant and can link genotype to pheno-
type in metabolic disorders.
INTRODUCTION
Metabolism is primarily or secondarily affected in several ac-
quired and inherited human diseases. Characterization of the
metabolic changes occurring in health and disease states has
a wide range of implications, from elucidation of pathogenetic
mechanisms to development of new biomarkers and drug
discovery.
Inborn errors of metabolism (IEMs) are a group of Mendelian
disorders resulting from genetic disruption of single metabolic
enzymes. A large number of these reactions occurs in the liver.2292 Cell Reports 15, 2292–2300, June 7, 2016 ª 2016 The Author(s
This is an open access article under the CC BY license (http://creativeThe study of these disorders has been instrumental to under-
standing the physiological consequences of metabolic reactions
and pathogenesis of more common multifactorial diseases. In
contrast to Mendelian diseases, which are due to severe impair-
ment of single-enzyme reactions, common multifactorial dis-
eases may result from mild impairment of several metabolic re-
actions (Lanpher et al., 2006). Nevertheless, our understanding
of the consequences of single-enzyme deficiencies on meta-
bolism as a whole are underappreciated, since most studies
have been narrowly focused on the affectedmetabolic reactions,
thus neglecting alterations of more distant metabolites. In most
patients affected with IEMs, there are few therapeutic options
that are often limited to common sense interventions aimed at
either reducing the substrate or increasing the product of the
affected reaction.
Tissue-specific genome-scale metabolic models, which have
only recently become available through the efforts of the
modeling community, allow in silico prediction of the effects of
genetic or chemical perturbations on human metabolism (Gille
et al., 2010; Jerby et al., 2010; Shlomi et al., 2009; Thiele et al.,
2013). These computational models have been used to predict,
for example, cancer drug targets (Folger et al., 2011), anti-aging
drugs (Yizhak et al., 2014), and biomarkers for rare metabolic
disorders (Duarte et al., 2007; Shlomi et al., 2009; Thiele et al.,
2013).
Here we applied a computational approach to predict and
analyze the metabolic alterations occurring in hepatocytes lack-
ing alanine:glyoxylate aminotransferase (AGT), a peroxisomal
enzyme encoded by the AGXT gene and mutated in primary
hyperoxaluria type 1 (PH1).
PH1 is an autosomal recessive disease that presents with hy-
peroxaluria, progressive renal involvement, and systemic depo-
sition of calcium oxalate in multiple organs and tissues. Although
the enzyme is only expressed in hepatocytes, lack of AGT results
in excessive production of oxalate by the liver, leading to oxa-
late-induced damage in several tissues, particularly in kidneys.
PH1 is a severe disease that results in high morbidity, pain,
disability, poor quality of life, and early death if treated late or).
commons.org/licenses/by/4.0/).
left untreated. Effective treatments for PH1 are still lacking
and combined liver-kidney transplantation is the only available
therapeutic option for patients with severe forms (Hoppe et al.,
2009).
PH1was chosen for our computational metabolicmodeling for
the following reasons: (1) the defective enzyme is expressed only
in the liver, (2) enzyme deficiency does not result in structural
changes of the liver that could secondarily affect metabolic func-
tions, and (3) a mousemodel is available to readily investigate al-
terations predicted by the computational approach (Salido et al.,
2006). We demonstrated in vitro, in vivo, and in the sera of PH1
patients that current genome-scale metabolic models are now
sufficiently detailed to enable in silico prediction of the patho-
physiologic consequences of a single-enzyme deficiency and
to suggest therapeutic targets. We correctly identified metabo-
lites known to accumulate in PH1, such as glyoxylate, glycolate,
and oxalate, but also discovered a link between AGT and the
metabolism of histidine and histamine. Moreover, we proved
that such models can be used to identify and validate potential
therapeutic enzyme targets for PH1.
RESULTS
Computational Approach to Predict Metabolic
Alterations Due to Single-Enzyme Defect in
Hepatocytes
We applied a computational systems-level approach to simulate
in silico metabolic alterations in hepatocytes due to the gain of
function (GoF) or loss of function (LoF) of a single enzyme starting
from a recently published genome-scale metabolic network
model of human hepatocytes (HepatoNet1). The in silico model
comprises 777 metabolites and 2,539 reactions across eight
compartments (Gille et al., 2010).
We first extendedHepatoNet1 by including 50 additional enzy-
matic and transport reactions and eight metabolites (Table S1)
related to glyoxylate metabolism that were needed to model
PH1, including the reaction carried out by AGT. One of the reac-
tions we added is the cytosolic alanine-glyoxylate transamina-
tion carried out by the glutamic-pyruvate transaminase (GPT),
also known as alanine aminotransferase (ALT) (Donini et al.,
2009). Hence, in the extended model, GPT catalyzes in the cyto-
plasm the same reaction as AGT in the peroxisome, in addition to
its canonical function (glutamate-pyruvate or alanine-transami-
nase), already present in the original model.
We next applied an algorithm we recently proposed, differen-
tial flux-balance analysis (DFA), to predict differences in meta-
bolic fluxes and metabolite levels between wild-type (WT) and
single-enzyme-defective hepatocytes across 442differentmeta-
bolic objectives (Table S2) (Pagliarini and di Bernardo, 2013). Of
these, 123 simulate physiological hepatic functions (e.g., ATP
production and amino acid degradation), while the remaining
319 are used for model validation (Gille et al., 2010).
DFA is based on flux balance analysis (FBA), a standard math-
ematical procedure to semiquantitatively estimate the metabolic
flux of each metabolic reaction in a genome-scale model at
steady state (i.e., no accumulation or depletion of metabolites)
when satisfying a given metabolic objective (e.g., consume
amino acids to produce glucose) (Orth et al., 2010). For eachmetabolic objective, DFA computes the difference between the
metabolic fluxes predicted by FBA in the WT genome-scale
model versus the perturbed model (LoF or GoF of a single
enzyme or of a set of them). The LoFmodel lacks the enzyme un-
der investigation, whereas the GoF model is constrained so that
the reaction(s) carried out by the enzyme of interest is forced to
be more active than in the WT. The end result is a ranked list of
metabolic fluxes of all the reactions in the model (2,589), sorted
by their difference in the LoF (or GoF) model versus the WT
model. This difference is computed as the average across the
442 metabolic objectives. Hence, the reactions that are most
affected by the LoF (or GoF) will be found at the top of the ranked
list. Once these differential metabolic fluxes have been identi-
fied, the metabolites (785) involved in the associated reactions
are ranked to predict the most affected ones. This is done, for
each metabolite, by summing the contribution of all the differen-
tial fluxes involving the same metabolite. This value is then used
for the ranking, so that the metabolites whose fluxes are most
affected by the LoF (or GoF) will be found at the top of the ranked
list. Finally, we applied a modified version (Experimental Proce-
dures) of flux variability analysis (FVA) (Duarte et al., 2007; Shlomi
et al., 2009; Thiele et al., 2013) to the top-ranked metabolites to
estimate whether these tend to increase or decrease in the LoF
(or GoF) model compared to the WT model.
In Silico Model of PH1
We applied DFA and FVA on the extended HepatoNet1 model to
simulate the effect of AGT enzyme LoF, causative of PH1. We
thus obtained a ranked list of 590 metabolites (Table 1; Table
S3), obtained from the list of 785 metabolites after removing
small molecules, co-factors, and pooled metabolites in Table
S2, and a list of 2,589 reactions (Table S3) ranked according to
their predicted change following AGT LoF. We observed that
hundreds of reactions, which are not directly related to peroxi-
somal AGT, are perturbed throughout the metabolic network
and across multiple cellular organelles (Table S3). Interestingly,
the AGT-like glyoxylate detoxification reactions carried out by
AGXT2 inmitochondria andGPT in the cytoplasm increased their
flux following AGXT LoF (Table S3; Figure S1). However, these
compensatory effects were not sufficient to normalize oxalate
levels (Table 1; Table S3), in agreement with disease develop-
ment in affected patients.
The significance of model predications was assessed by
metabolite set enrichment analysis (MSEA) (Xia and Wishart,
2010). MSEA is a statistical procedure for metabolomic studies
that takes as input a list of altered metabolites in a patient and
automatically predicts the most likely metabolic disorder. This
is done by checking whether the metabolites in input are statis-
tically enriched for known biomarkers of the disease. The top 50
metabolites predicted to change the most by the in silico model
of PH1 (Table S3) were used to run MSEA. MSEA ranked PH1 as
the most likely disease of 346 diseases (Table S3, p value =
0.00117).
The metabolites predicted to change the most by the in silico
analysis (i.e., ranked in the top 50 positions, Table S3) included
all the three major urine and plasma biomarkers of PH1 patients
(Table 1; Table S3), i.e., the disease-causing oxalate, glycolate,
and glyoxylate (Danpure, 2006). In addition to the known diseaseCell Reports 15, 2292–2300, June 7, 2016 2293
Table 1. The Top 20 Metabolites of 590 Whose Concentrations
Are Predicted to Be Altered the Most by DFA as a Result of
AGT LoF
Rank (Differential
Flux Balance) Metabolite Name KEGG ID
Predicted
Change (FVA)
1 serine C00065 
2 alanine C00041 =
3 pyruvate/
hydroxypyruvate
C00022/
C00168

4 glyoxylate C00048 +
5 glycine C00037 +
6 glycerate C00258 
7 glycolate C00160 +
8 glycolaldehyde C00266 =
9 glyceraldehyde C02154 
10 hypoxanthine C00262 +
11 xanthine C00385 =
12 glutamate C00217 
13 oxaloacetate C00036 +
14 glutathione C00051 =
15 glutathione disulfide C00127 =
16 histidine C00135 =
17 a-ketoglutarate C00026 
18 histamine C00388 
19 thymine C00178 =
20 dihydrothymine C00906 =
Metabolites are ranked by summing up the contribution of all differential
fluxes involving each metabolite. The metabolites known to accumulate
in the urine of PH1 patients (glyoxylate, glycolate, and oxalate) (Xia and
Wishart, 2010) are shown in italic. Oxalate is ranked at position 39 of
590 (Table S3), hence it is not shown in this table. Column 4 reports the
predicted sign of change in metabolite concentrations as computed by
FVA (Supplemental Experimental Procedures): the metabolite concentra-
tion can be elevated (+), reduced (), or (=) no sign could be predicted by
FVA. Small molecules (e.g., water and carbon dioxide), co-factors (e.g.,
NADP and ATP), and a set of other metabolites were not considered
because they are involved in a large number of reactions. The complete
list of all metabolites and co-factors is reported in Table S2. Details on
the analysis can be found in the Supplemental Experimental Procedures.
See also Figure S1 and Tables S2 andS3, which contains the complete list.biomarkers, several other metabolites listed in Table 1 were ex-
pected to change: pyruvate, alanine, and glycine are directly
involved in the AGT reaction; hydroxypyruvate is oxidized to
glycerate by glyoxalate reductase/hydroxypyruvate reductase
(GRHPR), the enzyme deficient in primary hyperoxaluria type 2
(PH2) that catalyzes the reduction of glyoxylate to glycolate
(Cramer et al., 1999); serine also was expected to change
because of the serine-pyruvate transaminase activity of AGT
(Danpure, 2006).
In contrast, other metabolites such as glutamate and a-keto-
glutarate (aKG) were unexpected, but the most surprising
and interesting metabolites were histamine and its precursor
histidine, whose levels were predicted to be altered in the AGT
LoF model. Histamine is a biogenic amine with central roles
in allergic responses and gastric acid secretion, involved in2294 Cell Reports 15, 2292–2300, June 7, 2016regulation of immune response, inflammation-associated carci-
nogenesis, and neurotransmission. Histamine is endogenously
generated from its precursor histidine by the histidine-decarbox-
ylase in several tissues (Rosenthaler et al., 1965), including liver
(Tran and Snyder, 1981), and this reaction was already present in
HepatoNet1. So far, no relationship between histidine, or hista-
mine, and AGT deficiency in PH1 has been reported.
Histidine and Histamine Are Reduced in PH1
We measured liver and serum levels of aKG, histamine, and his-
tidine in the Agxt/ mouse model of PH1 that recapitulates the
biochemical features of PH1 patients (Salido et al., 2006) to vali-
date the in silicomodel, which predicted non-obvious changes in
these three metabolites (Table 1). Consistent with the in silico
result (Table 1), aKG was significantly reduced in Agxt/mouse
serum (Figure S2A) compared to control mice.
Histamine levels in liver and serum were also significantly
reduced in Agxt/ mice compared to WT mice (Figures 1A
and 1B). Histamine levels were increased compared to control
uninjected Agxt/ mice (Figures 1A and 1B) when hepatic
AGT expression was restored in Agxt/mice by intravenous in-
jection of a helper-dependent adenoviral vector encoding AGT
under the control of a liver-specific promoter (HDAd-AGT) (Bru-
netti-Pierri and Ng, 2011; Brunetti-Pierri et al., 2005; Castello
et al., 2016) (Figure S3A). Histamine levels were unaffected in
Agxt/ mice injected with HDAd-AFP, a vector expressing the
unrelated reporter gene a-fetoprotein under the control of the
same expression cassette (serum histamine: 2.14 ± 0.85 ng/
ml; n = 5). In addition, compared to WT controls, Agxt/ mice
had decreased vascular permeability, a functional readout of his-
tamine-mediated response, whichwas restored by liver-directed
AGXT gene transfer (Figures 1C and 1D). Decreased histamine
levels were also detected in AGXT knockdown human Huh-7
hepatic cells (Figure 1E; Figure S3B; Experimental Procedures)
and in plasma of PH1 patients with confirmed AGXT mutations
(Figure 1F; Table S3).
Histidine, the histamine precursor, was also significantly
reduced inAgxt/mouse liver (Figure 1G) and serum (Figure 1H)
compared to control mice, consistent with the in silico results
(Table 1). However, histamine concentration in normal human
plasma is in the nanomolar range, whereas histidine concentra-
tion is in the micromolar range. Therefore, it is not obvious that a
reduction in histidine levels should result in systemic reduction
of histamine levels. To address this issue, we performed intra-
peritoneal injections of histidine in both WT and Agxt/
mice that resulted in increased serum histamine levels when
compared to baseline levels (Figure 1I). This result confirms
that changes in systemic histidine concentration can affect
serum histamine levels in mice despite their great difference in
plasma concentrations, as reported also in previous studies
(Yoshikawa et al., 2014).
AGT LoF Affects the Histidine Degradation Pathway
The in silico PH1 model revealed unexpected changes in histi-
dine and histamine levels as a consequence of AGT LoF, which
we confirmed both in vitro and in vivo.
The in silico analysis revealed a global perturbation of meta-
bolism throughout the network, thus several different reactions
Figure 1. Reduction of Histamine in PH1 Mice and Patients and in Cells Knocked Down for AGT
(A and B) Histamine levels in livers (A) and sera (B) were reduced in Agxt/mice compared to wild-type (WT) mice (at least n = 3 per group). Agxt/mice with
vector-mediated expression of AGT protein showed increased histamine in both livers (A) and serum (B).
(C) Compared toWTmice, Agxt/ showed reduced Evans blue extravasation in turned-over skin after intravenous injection of Evans blue followed by intradermal
injections of either saline or compound 48/80.
(D) The ratio of fluorescence units given by intradermal injection of 48/80 and normal saline was reduced in Agxt/ mice (n = 8 per group).
(E) AGT-knockdown Huh-7 cells (AGT KD, Figure S3B) had reduced intracellular histamine compared to WT cells.
(F) Plasma histamine levels were reduced in PH1 patients harboring AGXT mutations (Table S2; n = 3) compared to normal subjects (n = 5).
(G and H) Histidine levels were reduced in livers (G) and sera (H) of Agxt/ mice compared to WT.
(I) Intraperitoneal injections of histidine resulted in increased histamine levels at 24 hr after the injections (T24) compared to baseline levels (T0) in both Agxt/ and
control WT mice (n = 6 per group; *p < 0.05).
See also Figures S1, S2, and S3.might contribute to this effect. To better elucidate the most rele-
vant pathways, we again applied MSEA to the metabolites most
affected by AGT LoF in Table 1, but this time to investigate
whether they were significantly enriched in known metabolic
pathway(s) (rather than disease biomarkers) (Experimental Pro-
cedures). As shown in Table S3, the most significant pathways
(p < 0.05) included amino acid metabolism (alanine, glycine,
glutamate, and histidine), glutathione metabolism, ammonia re-
cycling, and urea cycle. These last two pathways are involved
in histidine degradation and glutamate metabolism. In addition,
we noticed that aKG, alanine, pyruvate, and glutamate, all pre-
sent in Table 1, are the metabolites involved in the alanine-trans-
amination reaction (aKG + alanine / pyruvate + glutamate)
carried out by GPT, the most abundant enzyme in liver, with acentral role in glutamate metabolism (Figure 2). Moreover,
according to the in silico model, the GPT-mediated alanine-
transamination reaction increases its flux following AGT LoF (Fig-
ure S1; Table S3; Supplemental Experimental Procedures).
We next asked why AGT LoF should affect the flux through
GPT and in turn affect histidinemetabolism. As shown in Figure 2
and Figure S1 and detailed in the Supplemental Experimental
Procedures, according to the model, the fluxes through GPT in-
crease because alanine is no longer consumed by AGT in the
peroxisome and it is thus available to GPT in the cytoplasm (Fig-
ure 2; Figure S1; Table S3). Hence, both reactions carried out by
GPT in the cytoplasm (the glyoxylate-transamination reaction
and the alanine-transamination reaction producing pyruvate
and glutamate) increase their flux (Table S3).Cell Reports 15, 2292–2300, June 7, 2016 2295
Figure 2. The In Silico Metabolic Model Re-
veals a Link between AGT LoF and Histidine
Metabolism Mediated by the Action of GPT
Both AGT- and GPT-mediated reactions involve
alanine, glyoxylate, glycine, and pyruvate. GPT
catalyzes two different reactions in heptocytes: the
non-canonical glyoxylate detoxification reaction
and the canonical reversible transamination be-
tween alanine and a-ketoglutarate to generate py-
ruvateandglutamate.Glutamate isa keycompound
in amino acid degradation. Alteration of metabolic
fluxes caused by AGT LoF are thus propagated via
GPT to histidine metabolism. Histidine can be
metabolized to glutamate and a-ketoglutarate via a
step of intermediary reactions (double arrows) and/
or to histamine. The conversion of histidine into
histamine also occurs in other cell types.
See also Figure S1 and Tables S1, S2, S3, and S5.The increase in the flux toward pyruvate and glutamate directly
affects histidine metabolism because histidine can only be
degraded to glutamate in the liver (or redirected to histamine
but to a much lesser extent, because histamine is found in the
nanomolar range whereas histidine is in the micromolar range).
Specifically, according to the model, the increase in glutamate
production results in increased flux through the urea cycle,
allowing more histidine to be degraded to glutamate (Table
S3; Supplemental Experimental Procedures). These results are
consistent with the experimental results (Figure 1).
However, since the in silico metabolic model does not in-
clude reactions involved in intracellular histamine degradation
(e.g., histamine N-methyltransferase [HMT] catalyzing the con-
version of histamine into N-methyl-histamine), we cannot rule
out an additional contribution of these reactions to the observed
phenotype. Therefore, we measured N-methyl-histamine in
Agxt/ mice, which was found to be increased compared to
WT mice (Figure S2B).
To further probe the role of GPT in PH1, we also simulatedGPT
GoF in silico in the context of AGT LoF. As GPT carries out two
reactions in the model (alanine transamination and glyoxylate
transamination), we simulated an increase in the flux of both re-
actions. As reported in Table S4, the model predicts a reduction
of oxalate levels induced by GPT GoF and a decrease in the his-
tidine degradation flux. Unsurprisingly, if we simulate an increase
only in the flux through the alanine-transamination reaction, but
not through the glyoxylate-transamination reaction, then no
reductions in oxalate levels and in histidine degradation are
predicted to occur (Supplemental Experimental Procedures).
In conclusion, as shown in Figure 2, the reduction of histidine
levels in PH1 is explained by an increase in the degradation of
histidine in hepatocytes, mediated by GPT, and caused by an
increased availability of alanine. The increased histidine degra-
dation thus causes a decrease in histidine levels and hence in
histamine levels.
AlanineReducesHistamine Levels inWTMicewhileGPT
Overexpression Restores Normal Histamine Levels and
Reduces Urinary Oxalate in PH1 Mice
According to the in silico model, histidine/histamine reduction in
AGT LoF occurs because alanine is redirected from AGT to GPT2296 Cell Reports 15, 2292–2300, June 7, 2016and thus secondarily alters histidine metabolism (Figure 2; Fig-
ure S1). If this is correct, then an excess of alanine in a WT
context should cause a decrease of histamine levels systemi-
cally, whereas in PH1mice there should be a weaker or no effect,
as histamine is already reduced.
To validate this prediction, we investigated the effects of
short-term alanine administration in mice. Intraperitoneal in-
jection of alanine in WT mice resulted in decreased serum his-
tamine levels at 2 hr compared to baseline levels, but no effects
were detected in Agxt/mice (Figure 3A; Figure S2C). The lack
of response in Agxt/ mice was expected, since in these mice
histamine levels are already low, while the flux through GPT is
increased because of the AGT LoF. The experimental validation
of this non-obvious prediction of the model supports the
simplified model in Figure 2 linking glyoxylate detoxification to
histidine metabolism.
To verify that GPT overexpression can restore normal histidine
and histamine levels, as predicted in silico, at least when GPT
can carry out also the non-canonical AGT-like reaction, we over-
expressed GPT in Agxt/ mice by an HDAd-Gpt vector encod-
ing the murine GPT enzyme under the control of a liver-specific
expression cassette (Brunetti-Pierri and Ng, 2011; Brunetti-Pierri
et al., 2005). Gpt gene transfer was confirmed by increased
serum GPT levels (Figure 3B). Importantly, hepatic GPT overex-
pression increased serum histamine in PH1 mice (Figure 3C) to
levels similar to those measured in WT mice (Figure 1B). Histi-
dine, which was reduced in Agxt/ mice, increased following
GPT overexpression (Figure 3D). Moreover, GPT overexpression
increased vascular permeability in Agxt/ mice (Figure 3E).
Finally, we also detected a decrease in urinary oxalate levels
in HDAd-Gpt-injected Agxt/ mice compared to uninjected
Agxt/ mice (Figure 3F), thus supporting GPT as a potential
therapeutic target for PH1 therapy (Donini et al., 2009).
In conclusion, our in silico and experimental results support
the simplified model of metabolism schematized in Figure 2
and Figure S1: the flux through the glutamate-pyruvate-transam-
ination reaction carried out by GPT increases because alanine,
which is no longer consumed by AGT, is redirected to GPT to
produce pyruvate and glutamate. This perturbation in glutamate
production has a direct effect on the flux through the histidine
degradation pathway toward glutamate.
Figure 3. Alanine Administration Reduces
Histamine Levels in WTMice, while GPT He-
patic Overexpression Increases Histamine
Levels and Vascular Permeability and Re-
duces Urinary Oxalate in Agxt/ Mice
(A) Intraperitoneal injections of alanine reduced
histamine levels at 2 hr after the injections (T2h)
compared to baseline levels (T0) in WT mice (n = 5
per group).
(B) Intravenous injection of HDAd-Gpt vector ex-
pressing the mouse Gpt gene under the control of
a liver-specific expression cassette (Brunetti-Pierri
and Ng, 2011; Brunetti-Pierri et al., 2005) resulted
in high serum concentration of GPT protein in
Agxt/ mice (n = 5 per group).
(C and D) Serum histamine (C) and histidine (D)
levels were significantly increased in GPT-over-
expressing mice.
(E) Vascular permeability measured as ratio of
fluorescence units of Evans blue extracted from
skin over saline after intradermal injection of 48/80
was increased in Agxt/ mice injected with
HDAd-Gpt compared to controls (n = 8 per group).
(F) Compared to baseline (T0) urinary oxalate was
reduced at 12 weeks (T12w) post-injection in
Agxt/mice injectedwithHDAd-Gpt (E). *p<0.05.
See also Figures S1 and S2 and Table S4.DISCUSSION
Mammalian intermediary metabolism was defined several years
ago in biochemical terms from in vitro studies, but we are still
lacking aclear picture of in vivometabolismasawhole.Metabolic
reactions are interconnected in a complex biochemical network
where LoF of a single enzymemay result in perturbations of mul-
tiple, distant metabolic pathways. However, understanding how
alterations in one pathway affect other pathways, which may
appear remote from the initial metabolic defect, remains elusive.
Here, we show that human genome-scale metabolic models,
coupled to appropriate computational approaches, can be
effectively used to model in silico a liver IEM and to obtain clini-
cally relevant results.
We demonstrated that deficiency of AGT unexpectedly results
in reduced histidine and histamine levels, presumably through an
increase in histidine catabolismmediated by GPT and caused by
a redirection of the alanine flux from AGT in the peroxisome
toward GPT in the cytosol. In agreement with the model predic-
tions, we demonstrated in vivo in WT mice that increasing
systemic levels of histidine results in increased serum levels of
histamine, whereas increasing systemic levels of alanine results
in decreased serum histamine.
A limited number of mammalian cells, namely mast cells and
other immune cells, gastric enterochromaffin-like cells, and
histaminergic neurons, express histidine decarboxylase, which
is involved in histamine production. In the liver, hepatocytes,
biliary epithelial cells, oval cells, and dendritic cells can convert
histidine to histamine (Chang et al., 2010). Using a hepatocyte-
derived cell line, we were indeed able to detect reduced hista-
mine following AGT knockdown.
Our study suggests that molecules blocking AGT might
reduce histamine systemically by depleting systemic levels ofhistidine, the substrate of histamine decarboxylase. Neverthe-
less, if developed, these antihistamine drugs should be used
with caution because of potential oxalosis, which might occur
because of severe and sustained reduction of AGT activity.
In addition, we demonstrated both in silico and in vivo that the
increase in oxalate caused by AGT LoF is partly rescued by GPT
overexpression. Hence, we confirmed GPT as amodifier gene or
potential drug target for oxalate detoxification in patients with
hyperoxalurias either primary or secondary. There have been
great efforts to develop liver-directed gene therapy for IEMs
(Piccolo and Brunetti-Pierri, 2015). Vectors encoding genes
that are not functioning in disease state (i.e., AGXT in PH1) are
obviously the first choice for gene therapy. Nevertheless, for
PH1 patients harboring null mutations, who are at an increased
risk for an immune reaction against the transgene product,
gene therapy with the gene encoding for GPT would be an
alternative option. Moreover, GPT expression can be com-
bined within the gene therapy vector expressing AGT to further
improve therapeutic efficacy.
Gene therapy with viral vectors has proven to be more difficult
than initially anticipated, and immune system reactions against
viral vectors and risks of insertional carcinogenesis remain
important obstacles for clinical translation. Therefore, develop-
ment of pharmacologic approaches based on small molecule
drugs remains attractive. Toward this goal, the data gener-
ated in this study also could be exploited for therapy of PH1
by searching for human-approved drugs able to increase
GPT expression. Besides applications for PH1 therapy, drugs
reducing hyperoxaluria by GPT overexpression might be effec-
tive also for treatment of other forms of primary hyperoxalurias
(e.g., PH2 and PH3) and more common forms of secondary hy-
peroxaluria (Xu et al., 2013). Our computational approach could
be applied to identify additional drug-treatable targets to restoreCell Reports 15, 2292–2300, June 7, 2016 2297
physiological levels of metabolites, which are altered in Mende-
lian or even complex multifactorial disorders. Indeed, in the case
of PH1, it would be possible to identify enzymes whose overex-
pression or knockdown results in reduced oxalate levels.
Our work has implications for PH1 patients as well as for
patients affected by other metabolic diseases. Genome-scale
metabolic models painstakingly built up from scratch by the
modeling research community (Gille et al., 2010; Jerby et al.,
2010; Thiele et al., 2013) might be applied to a large number
of disorders, potentially leading to new knowledge on disease
pathogenesis and to the identification of therapeutic targets.
In summary, our results show that a single-enzyme LoF results
in dysregulation of several metabolic reactions, going beyond
the classic view on the pathogenesis of a Mendelian disease,
which is narrowly focused on the affected pathway in which
the enzyme operates.
More than a century ago, Archibald Garrod proposed the
concept of ‘‘chemical individuality,’’ suggesting that even
healthy individuals are biochemically unique due to inherited dif-
ferences in enzymes, which are reflected in a predisposition to
multifactorial diseases (Childs, 1970). In a more contemporary
perspective, this concept is reflected in individualized medicine
and metabolomic profiling that can detect individuals at higher
risks of developing specific diseases to develop targeted
preventive or therapeutic interventions. As metabolic profiling
based on tandem mass spectrometry (MS/MS) and nuclear
magnetic resonance (NMR)-based technologies is becoming
more widely used for diagnostics, the major challenges facing
metabolomics are to determine whether abnormal metabolites
are indeed involved in pathogenesis or can act as disease
biomarkers correlating with disease severity. Computational
approaches based on genome-scale metabolic models might
assist in interpreting and validating large-scale metabolic
alterations.EXPERIMENTAL PROCEDURES
Extension and Analysis of the Genome-Scale Metabolic Model of
Hepatocytes for PH1
The in silico metabolic network was described by a stoichiometric matrix
(Pagliarini and di Bernardo, 2013) (Supplemental Experimental Procedures).
A stoichiometric matrix contains information about all the metabolic transfor-
mations, and it is formed from the stoichiometric coefficients of each reaction
that comprise themetabolicmodel, which commonly are integer numbers. Re-
actions and metabolites present in HepatoNet1 (Gille et al., 2010) network
model were extended by including the following: (1) reactions and compounds
known to be involved in glyoxylate metabolism, starting from published
models (Duarte et al., 2007; Ma et al., 2007), public databases (Cerami et al.,
2011; D’Eustachio, 2011; Kanehisa and Goto, 2000), and literature analysis
(Cochat et al., 2012; Danpure, 1986; Donini et al., 2009); (2) transport reactions
useful to balance the metabolic fluxes in the different compartments; and (3)
metabolic routes, related to the amino acids that have been shown to be con-
verted to oxalate, but which have not been completely defined yet (Asplin,
2002; Nguyen et al., 2001).
To validate the extended in silico model, we performed FBA to establish a
flux distribution for each of the different metabolic objectives listed in Table
S2. The principle of flux minimization (Holzh€utter, 2004) was applied to opti-
mize the metabolic objective and to compute an optimal metabolic flux,
obtained as the solution of a constrained linear optimization problem. We
also performed producibility analysis to check that the model was indeed
able to produce all the compounds involved in glyoxylate metabolism. We2298 Cell Reports 15, 2292–2300, June 7, 2016defined a metabolite xi as producible if the network can sustain its synthesis
under the steady-state and thermodynamic constraints. To test the producibil-
ity of xi, we added a reaction in the cytoplasmic compartment consuming xi,
and then a flux-balance problem was solved to check if the in silico network
was able to produce a strictly positive flux through this reaction. More details
can be found in the Supplemental Experimental Procedures.
Simulating Single-Enzyme LoF or GoF
To simulate the effect of an LoF of an enzyme ej catalyzing the reaction rj, we
solved 442 optimization problems, corresponding to the 442 metabolic objec-
tives and physiological functions reported in Table S2, by constraining the
fluxes through rj to zero. The same optimization problems were then solved
for theWTmodel, but this time by constraining the fluxes through rj to be larger
than an activity threshold. The results of these simulations were stored in two
matrices that contained the metabolic fluxes of each reaction across the
different metabolic objectives, in the WT and LoF simulations, respectively
(Supplemental Experimental Procedures).
To simulate a GoF of ej, we followed a similar procedure, but this time con-
straining the fluxes through rj to be greater at least ten times more than their
value in the WT model (Supplemental Experimental Procedures).
DFA and FVA
DFA is described in Pagliarini and di Bernardo (2013) and in the Supple-
mental Experimental Procedures. DFA aims at identifying the metabolites
and reactions that are most affected by an enzyme LoF or GoF. Small mol-
ecules (e.g., water and carbon dioxide), cofactors (e.g., NADP and ATP),
and a set of metabolites were not included, because they were involved
in a large number of reactions (Table S2). DFA is based on computing
FBA across 442 metabolic objectives for both the WT model and the per-
turbed model (i.e., with single-enzyme knockout or overexpression, or any
combination of both). The average flux carried by each reaction across
the 442 metabolic objectives for each of the two models is computed. For
each reaction, we then take the difference of the average flux in the WT
model minus its value in the modified model, expressed as a percentage
of the WT flux. These differential fluxes are then used to rank the reactions
from the ones that change the most in the modified model to the ones that
change the least or do not change at all. Metabolites are then ranked
according to the sum of the absolute values of the differential fluxes (Sup-
plemental Experimental Procedures).
DFA allows us to compute the change in the concentration of ametabolite as
result of an enzyme LoF or GoF, but not its sign. To establish if this concentra-
tion is expected to be elevated, reduced, or unchanged, we applied FVA
(Duarte et al., 2007; Shlomi et al., 2009; Thiele et al., 2013). In FVA, an ex-
change interval for each metabolite is computed both in the WT model and
in the LoF (GoF) model. This interval denotes the minimal flux and maximal
flux of a metabolite that can be supported by the metabolic model. For each
metabolite, FVA compares the exchange interval in WT model with the one
in the LoF (GoF) model. If the two intervals overlap, then the metabolite is
not affected by the enzyme LoF (GoF). Otherwise it is increased or decreased
depending on the relative values of the two intervals (Supplemental Experi-
mental Procedures). The code to run all of the simulations performed in this
study can be found online (http://dibernardo.tigem.it).
MSEA
MSEA is a bioinformatic tool to identify biologically meaningful patterns
that are significantly enriched in metabolomic data and metabolic pathways
(http://www.metaboanalyst.ca/) (Xia and Wishart, 2010). MSEA works by
comparing the metabolites in a set to pre-defined functional groups. To iden-
tify the most likely diseases in Table S3, we used as input for the MSEA anal-
ysis the top 50 metabolites in Table S3 (Kyoto Encyclopedia of Genes and
Genomes [KEGG] identifiers), and then we applied the over-representation
analysis (ORA) of the MSEA online tool selecting the urine disease-associated
metabolite sets option. To obtain the most significant pathways in Table S3,
we used as input the top 20 metabolites in Table 1 and applied again the
ORA, but this time selected the pathway-associated metabolite sets option.
The list of pathways in Table S3 does not change significantly if we use the
top 50 metabolites rather than the top 20.
Mouse Procedures
Agxt/mice were described previously (Salido et al., 2006) and animal proce-
dures were performed in accordance to the regulation of the Italian Ministry
of Health. Agxt/ mice were maintained on a SV-129 background. Injections
of the HDAd vectors were performed in a volume of 200 ml in the retro-
orbital plexus of 3-month-old male mice. Blood samples were collected by
retro-orbital bleeding. SV-129 background age- and sex-matched mice
were used as controls.
Histamine-mediated skin permeability was determined through a gross
staining using the compound 48/80 (Enzo Life Sciences) as described previ-
ously (Donelan et al., 2006).
3-month-old male Agxt/mice were injected intraperitoneally with L-Histi-
dine (1 g/kg of body weight) and placed in metabolic cages for 24-hr urine
collection. Blood samples for serum histamine levels were collected by
retro-orbital bleeding 24 hr after histidine injections.
WT and Agxt/ 3-month-old male mice were injected intraperitoneally
with L-Alanine (1 g/kg of body weight). Blood samples for serum his-
tamine levels were collected by retro-orbital bleeding 2 hr after the alanine
injections.
HDAd Vectors
HDAd-AGT, HDAd-GPT, and HDAd-AFP vectors all bear the PEPCK-WL
expression cassette (Brunetti-Pierri et al., 2005, 2006), driving the expres-
sion of human AGXT or murine Gpt, respectively. HDAd was produced in
116 cells with the helper virus AdNG163 as described elsewhere (Pastore
et al., 2013).
Blood and Tissue Analyses
Histamine levels were determined in mouse serum and liver homogenates and
in human plasma by ELISA (Labor Diagnostika Nord). For histamine determina-
tion on liver lysates, organs were homogenized in PBS using a Tissue Lyser
(QIAGEN) and histamine levels were normalized for protein concentrations
that were determined using Bradford Reagent (Bio-Rad).
Histamine in human plasma samples from PH1 patients and age-matched
controls were analyzed by ELISA (IBL International). Methylhistamine was
measured by ELISA (IBL International) on 24-hr urine collection according to
the manufacturer’s protocol. Amino acids were measured by high-perfor-
mance liquid chromatography (HPLC) at the Biochemical Laboratories at
Baylor College of Medicine.
For western blotting, liver specimens were homogenized in radio-immu-
noprecipitation assay (RIPA) buffer and complete protease inhibitor cocktail
(Sigma), incubated for 20 min at 4C and centrifuged at 13,200 rpm for
10 min. Pellets were discarded and cell lysates were used for western blots.
Proteins were loaded on a 12% SDS-PAGE, and, after transfer to a polyvi-
nylidene fluoride (PVDF) membrane, blots were blocked with TBS-Tween-20
containing 5% non-fat milk for 1 hr at room temperature, followed by incu-
bation with primary antibody overnight at 4C. The primary antibodies used
were a rabbit anti-human AGT (Sigma) and rabbit anti-calnexin (Enzo Life
Sciences).
Human Huh-7 Hepatic Cell Line
Huh-7 cells were cultured at 37C with 5% CO2 in DMEM supplemented with
10% v/v fetal bovine serum and penicillin/streptomicin. Cells were transfected
with a plasmid containing a small hairpin RNA (shRNA) for AGXT gene (Ori-
Gene) using TransIT-LT1 transfection reagent according to the manufacturer’s
instructions (Mirus). Selection of transfected clones was performed starting
at 24 hr after transfection with 1 mg/ml puromycin, and single stably trans-
formed cell line clones were isolated. Downregulation of AGT was shown by
western blotting with primary rabbit polyclonal anti-AGXT (Sigma) and primary
monoclonal anti-calnexin antibody (Enzo Life Sciences). Horseradish peroxi-
dase (HRP)-conjugated antibodies were used as secondary antibody (GE
Healthcare).
Statistical Analyses
Experimental data are presented as mean ± SD. Statistical significance was
computed using the Student’s two-sided t test and p values < 0.05 were
considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.014.
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